[go: up one dir, main page]

AR099300A1 - Hexahidrofuropirroles como inhibidores de pde1 - Google Patents

Hexahidrofuropirroles como inhibidores de pde1

Info

Publication number
AR099300A1
AR099300A1 ARP150100339A ARP150100339A AR099300A1 AR 099300 A1 AR099300 A1 AR 099300A1 AR P150100339 A ARP150100339 A AR P150100339A AR P150100339 A ARP150100339 A AR P150100339A AR 099300 A1 AR099300 A1 AR 099300A1
Authority
AR
Argentina
Prior art keywords
compound
formula
pde1 inhibitors
hexahydrofuropirroles
cycloalkyl
Prior art date
Application number
ARP150100339A
Other languages
English (en)
Inventor
Kehler Jan
Kyhn Rasmussen Lars
Langgrd Morten
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58698416&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR099300(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of AR099300A1 publication Critical patent/AR099300A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se proporciona hexahidrofuropirroles como inhibidores de PDE1 y su uso como un medicamento, en particular para el tratamiento de trastornos neurodegenerativos y trastornos psiquiátricos. Reivindicación 1: Un compuesto que tiene la estructura de fórmula (1) donde R¹ se selecciona del grupo constituido por H, F, cicloalquilo C₃₋₆ y alquilo C₁₋₄; R² - R¹¹ se seleccionan del grupo constituido por H, alquilo C₁₋₃, cicloalquilo C₃₋₆, flúor, hidroxi y alcoxi C₁₋₆; y sales de adición de ácido farmacéuticamente aceptables del compuesto de fórmula (1), mezclas racémicas del compuesto de fórmula (1), o el isómero óptico y/o enantiómero correspondiente del compuesto de fórmula (1), y formas polimórficas del compuesto de fórmula (1), así como también formas tautoméricas del compuesto de fórmula (1).
ARP150100339A 2014-02-07 2015-02-05 Hexahidrofuropirroles como inhibidores de pde1 AR099300A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA201400069 2014-02-07

Publications (1)

Publication Number Publication Date
AR099300A1 true AR099300A1 (es) 2016-07-13

Family

ID=58698416

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP150100339A AR099300A1 (es) 2014-02-07 2015-02-05 Hexahidrofuropirroles como inhibidores de pde1

Country Status (25)

Country Link
US (1) US9718832B2 (es)
EP (1) EP3102584B1 (es)
JP (1) JP6532880B2 (es)
KR (1) KR20160115931A (es)
CN (1) CN106414459B (es)
AP (1) AP2016009344A0 (es)
AR (1) AR099300A1 (es)
AU (1) AU2015214214A1 (es)
CA (1) CA2935470A1 (es)
CL (1) CL2016001959A1 (es)
CR (1) CR20160322A (es)
DO (1) DOP2016000179A (es)
EA (1) EA201691335A1 (es)
EC (1) ECSP16071574A (es)
ES (1) ES2711085T3 (es)
GE (1) GEP201706795B (es)
IL (1) IL246718A0 (es)
MA (1) MA39230B1 (es)
MX (1) MX2016010168A (es)
PE (1) PE20161071A1 (es)
PH (1) PH12016501495A1 (es)
RU (1) RU2016130684A (es)
SG (1) SG11201606445YA (es)
TW (1) TW201611834A (es)
WO (1) WO2015118097A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3126354T3 (pl) 2014-04-04 2020-06-15 H. Lundbeck A/S Fluorowcowane chinazolino-THF-aminy jako inhibitory PDE1
MX390582B (es) 2016-12-28 2025-03-20 Dart Neuroscience Llc Star Compuestos de pirazolopirimidinona sustituida como inhibidores de fosfodiesterasas 2 (pde2)
DK3717488T3 (da) 2017-11-27 2021-12-13 Dart Neuroscience Llc Substituerede furanopyrimidinforbindelser som pde1-inhibitorer
JP7493460B2 (ja) 2018-05-25 2024-05-31 イントラ－セルラー・セラピーズ・インコーポレイテッド 有機化合物
WO2020210614A1 (en) 2019-04-12 2020-10-15 Intra-Cellular Therapies, Inc. Organic compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060183763A1 (en) * 2004-12-31 2006-08-17 Pfizer Inc Novel pyrrolidyl derivatives of heteroaromatic compounds
SI2057153T1 (sl) * 2006-07-10 2012-12-31 H. Lundbeck A/S (3-ril-piperazin-1-il) derivati 6,7-dialkoksikuinazolin, 6,7-dialkoksiftalazin in 6,7-dialkoksiizokuinolin
EP2231558B1 (en) * 2007-12-14 2014-09-03 Merck Sharp & Dohme Corp. 3,4-substituted pyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease

Also Published As

Publication number Publication date
US20160347759A1 (en) 2016-12-01
CA2935470A1 (en) 2015-08-13
AU2015214214A1 (en) 2016-07-14
TW201611834A (en) 2016-04-01
KR20160115931A (ko) 2016-10-06
CN106414459A (zh) 2017-02-15
HK1232214A1 (en) 2018-01-05
EP3102584A1 (en) 2016-12-14
IL246718A0 (en) 2016-08-31
DOP2016000179A (es) 2016-09-30
RU2016130684A (ru) 2018-03-15
JP2017505328A (ja) 2017-02-16
PE20161071A1 (es) 2016-10-30
US9718832B2 (en) 2017-08-01
ES2711085T3 (es) 2019-04-30
CR20160322A (es) 2016-09-16
PH12016501495A1 (en) 2017-02-06
JP6532880B2 (ja) 2019-06-19
CL2016001959A1 (es) 2017-02-24
MA39230A1 (fr) 2017-07-31
AP2016009344A0 (en) 2016-07-31
CN106414459B (zh) 2018-08-03
EA201691335A1 (ru) 2016-12-30
GEP201706795B (en) 2017-12-11
EP3102584B1 (en) 2019-01-16
WO2015118097A1 (en) 2015-08-13
MA39230B1 (fr) 2018-04-30
SG11201606445YA (en) 2016-09-29
ECSP16071574A (es) 2017-02-24
MX2016010168A (es) 2016-10-07

Similar Documents

Publication Publication Date Title
CU20170015A7 (es) Compuesto de (pirazolilamino) pirimidinil biciclo (3.2.1)oct-8-il
MX2022012313A (es) Oxisteroles y metodos de uso de los mismos.
CU20160188A7 (es) Compuestos de indazole substituidos como inhibidores de irak4
ECSP16072941A (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
MX2020001757A (es) Compuestos, sales de los mismos y metodos para el tratamiento de enfermedades.
CO2017004530A2 (es) 2-amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de bace1
MX375970B (es) Compuestos de triazolopirimidina y usos de los mismos.
ECSP16067303A (es) Heteroarilos y usos de estos
EA201691442A1 (ru) N-азаспироциклоалканзамещенные n-гетероарильные соединения и композиции для ингибирования активности shp2
DOP2017000066A (es) Compuestos y composiciones como inhibidores de quinasa raf
MX2022007436A (es) Inhibidores de la autotaxina y sus usos.
ECSP17028459A (es) 2-amino-6-(difluorometil)- 5,5-difluoro-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1
CO2017001528A2 (es) Compuestos novedosos de pirimidina sustituidos
CO2017001506A2 (es) Compuestos novedosos de pirimidina sustituidos
AR102981A1 (es) Inhibidores de la necrosis celular y métodos de preparación de los mismos
CR20170247A (es) 2-amino-5,5-difluoro-6-(fluorometil)-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1
CO2017001523A2 (es) Novedosas pirimidinas 2,5-sustituidas
CO2017001389A2 (es) Compuestos de azetidiniloxifenilpirrolidina
AR099300A1 (es) Hexahidrofuropirroles como inhibidores de pde1
UA117779C2 (uk) Піразини як модулятори gpr6
MX2017008373A (es) Compuestos, composiciones y metodos.
AR098802A1 (es) Quinazolin-thf-aminas como inhibidores de pde1
EA201892188A1 (ru) Соединения пирролотриазина в качестве ингибиторов tam
DOP2017000036A (es) Compuestos de azetidiniloxifenilpirrolidina
BR112018069612A2 (pt) compostos de pirroltriazina como inibidores de tam

Legal Events

Date Code Title Description
FB Suspension of granting procedure